Home > HbA1c reduction with GLP-1RA leads to lower risk of CV events in cardiovascular outcome trials

HbA1c reduction with GLP-1RA leads to lower risk of CV events in cardiovascular outcome trials

Presented By
Dr Mart Roosimaa , University of Tartu, Estonia
Conference
EASD 2020
The reduction of cardiovascular (CV) events in CV outcome trials (CVOTs) of glucagon-like peptide-1 receptor agonist (GLP-1RA) can be explained by a decrease in HbA1c. Sodium-glucose transport protein 2 inhibitors and GLP-1RA have not only shown glycaemic benefits in several trials, but also significant positive effects on CV risk. However, variability in outcomes of better glycaemic control with GLP-1RA has cast some doubt over whether improved glycaemic control mediated CV risk reduction with these agents. Dr Mart Roosimaa (University of Tartu, Estonia) and colleagues performed a meta-analysis to determine whether better glycaemic control was responsible for the GLP-1RA-mediated reduction in CV risk [1]. HbA1c levels were used as an indicator of glycaemic control, and for the primary outcome of absolute CV risk, the number of patients at risk was extracted for both GLP-1RA and placebo groups at multiple time points from each published GLP-1RA tri...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on